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ABSTRACT
Objectives: To determine maternal and neonatal
specific antibody levels to selected vaccine-preventable
infections (pertussis, Haemophilus influenzae type b
(Hib), tetanus and pneumococcus).
Design: Prospective cohort study.
Setting: A UK secondary care maternity unit (March
2011–January 2012).
Participants: Mothers and infants within 72 h of
delivery were eligible. Unwell individuals, mothers less
than 18 years of age, and infants born at less than
36 weeks gestation, or weighing less than 2500 g,
were excluded. HIV-infected mothers were included.
112 mother–infant pairs were recruited. Samples from
111 mothers and 109 infants (108 pairs) were
available for analysis.
Outcome measures: Specific antibody levels were
determined using standard commercial ELISAs.
Specific antibody to pertussis antigens (PT and FHA)
of >50 IU/ml, defined as ‘positive’ by the test
manufacturer, were interpreted as protective.
Antitetanus antibody titres >0.1 IU/ml and anti-Hib
antibody titres >1 mg/l were regarded as protective.
Results: Only 17% (19/111) of women exhibited a
protective antibody response against pertussis. 50%
(56/111) of women had levels of antibody protective
against Hib and 79% (88/111) against tetanus.
There was a strong positive correlation between
maternal-specific and infant-specific antibodies’
responses against pertussis (rs=0.71, p<0.001),
Hib (rs=0.80, p<0.001), tetanus (rs=0.90, p<0.001)
and pneumococcal capsular polysaccharide (rs=0.85,
p<0.001). Only 30% (33/109) and 42% (46/109)
of infants showed a protective antibody response to
pertussis and Hib, respectively. Placental transfer
(infant:mother ratio) of specific IgG to pertussis,
Hib, pneumococcus and tetanus was significantly
reduced from HIV-infected mothers to their HIV-
exposed, uninfected infants (n=12 pairs)
compared with HIV-uninfected mothers with HIV-
unexposed infants (n=96 pairs) by 58% (<0.001), 61%
(<0.001), 28% (p=0.034) and 32% (p=0.035),
respectively.
Conclusions: Low baseline antibody levels against
pertussis in this cohort suggest the recently
implemented UK maternal pertussis immunisation
programme has potential to be effective.
INTRODUCTION
The UK is currently experiencing a dramatic
increase in the numbers of cases of pertussis
(whooping cough). In 2012, there were 9741
ARTICLE SUMMARY
Article focus
▪ Despite renewed interest in maternal immunisa-
tion worldwide, and the recent introduction of
a national maternal pertussis immunisation
programme in the UK, baseline data on maternal
and infant specific antibody levels to pertussis
and other vaccine-preventable infections are
limited.
▪ Placental transfer of specific antibody from mother
to infant is of key importance to antibody-mediated
immunity in the first few months of life. Low
maternal antibody, or reduced placental transfer,
may result in suboptimal infant antibody levels,
increasing vulnerability to infection in the period
before primary vaccination is complete.
▪ This article reports maternal and neonatal specific
antibody levels to selected vaccine-preventable
infections (pertussis, Haemophilus Influenzae type
b (Hib), tetanus and pneumococcus) in a UK
mother–infant cohort.
Key messages
▪ Maternal and infant specific antibody levels against
pertussis are very low in this UK cohort; this sug-
gests the new UK maternal pertussis immunisation
programme has the potential to be effective.
▪ Maternal HIV infection is associated with a signifi-
cant reduction in placental transfer of IgG to pertus-
sis, Hib, pneumococcus and tetanus even in
women receiving highly active antiretroviral therapy.
Strengths and limitations of this study
▪ This study provides recent data on baseline levels
of specific antibody in mothers and newborns to
vaccine-preventable infections in a UK cohort. Our
results support the recently introduced maternal
pertussis immunisation programme in the UK.
▪ The main limitation of our study is enrolment of a
modest number of mother–infant pairs at a single
centre.
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laboratory-conﬁrmed cases of pertussis in England and
Wales, almost 10 times more than in 2011 (1119 cases)
or in 2008 (902 cases), the last peak year.1 The highest
incidence of disease has been observed among infants
less than 3 months of age, with all 14 pertussis-related
deaths in 2012 observed in this age group. These
infants, too young to beneﬁt from the protection pro-
vided by routine infant vaccination, died from a poten-
tially preventable infectious disease. In response, in
September 2012, the UK Department of Health
announced the introduction of a temporary maternal
pertussis immunisation programme in order to protect
young infants.2
A window of vulnerability, before primary vaccination is
complete, is not just associated with pertussis, but equally
exists for other vaccine-preventable infections where
maternal antibody levels are low. The underlying principle
of maternal immunisation is to boost maternal antibody
levels and therefore increase the placental transfer of anti-
body from mother to child, potentially beneﬁtting both
mother and infant. The concept of maternal immunisa-
tion is not new; maternal tetanus immunisation, for
example, has been successfully implemented in resource-
limited settings for over 40 years. It has proved to be a
highly effective strategy that can reduce the risk of neo-
natal tetanus mortality by over 90%.3
To predict the potential efﬁcacy of any new maternal
immunisation programme, it is necessary to determine
population baseline levels of protective antibody in
mothers and newborns. The aim of our study, under-
taken prior to the new maternal pertussis immunisation
programme, was to examine levels of maternal and neo-
natal speciﬁc antibody levels to pertussis, Haemophilus
inﬂuenzae type b (Hib), pneumococcus and tetanus in a
cohort of mother–infant pairs in a UK setting.
METHODS
Study population and study procedures
The study was conducted between March 2011 and
January 2012 at the Imperial College Healthcare NHS
Trust, London, UK. The study was approved by the
National Research Ethics Service, reference: 07/H0720/
178. The study was funded by the National Institute for
Health Research (NIHR) Biomedical Research Centre
based at the Imperial College Healthcare NHS Trust and
Imperial College London. Information was available to
mothers in the antenatal clinic and consenting eligible
women were recruited from the postnatal wards. All
mothers gave written informed consent to participation
for themselves and their infants. Mother–infant pairs were
eligible for the study if the mother had delivered a live-
born infant in the previous 72 h. Mother–infant pairs were
excluded if the mother was less than 18 years of age,
unwell or intending to leave the study area within the next
5 months. Infants were excluded if they were born at less
than 36 weeks gestation, weighed less than 2500 g or were
unwell. Maternal HIV infection was not an exclusion
criterion. Consecutive eligible women were enrolled in the
study, irrespective of HIV infection status.
Up to 5 ml of maternal peripheral venous blood and
1 ml of infant capillary blood were collected. All samples
were collected within 72 h of delivery. Serum was sepa-
rated and stored at −80°C until analysis by standard
commercial ELISAs.
Laboratory assays
Speciﬁc IgG to Bordetella pertussis antigens pertussis toxin
(PT) and ﬁlamentous haemagglutinin (FHA) were mea-
sured using SERION ELISA classic kits (ESR 120G,
Serion Immundiagnostica GmbH, Würzburg, Germany).
This assay measures antibody response to the antigens
PT and FHA. Results are reported as a collective IgG
response to these pertussis antigens. Limits of quantiﬁca-
tion for this assay were 10–1000 IU/ml. There is no
established correlate of protection for pertussis, for
either an antibody response to multiple or single anti-
gens; however, low levels of antibody are highly corre-
lated with susceptibility to infection.4–7 It is established
in the literature that a ‘positive’ or detectable diagnostic
test may be consistent with some measure of protection.8
Pertussis titres of >50 IU/ml were regarded as a positive
response by the manufacturer: a pertussis IgG response
>50 IU/ml was therefore interpreted as protective.
Levels of speciﬁc IgG antibodies against tetanus toxoid
were determined using SERION ELISA classic kits (ESR
108G, Serion Immundiagnostica GmbH, Würzburg,
Germany). Limits of quantiﬁcation of the assay were
0.05–5.00 IU/ml. Tetanus antibody levels were classiﬁed
as providing sufﬁcient protection if >0.1 IU/ml.9
Hib capsular polysaccharide-speciﬁc IgG present in
serum was measured using the VaccZyme Human
Anti-Hib Enzyme Immunoassay kit (MK016, The Binding
Site Ltd, Birmingham, England). Limits of quantiﬁcation
for the assay were 0.11–9.00 mg/dl. Anti-Hib antibody
titres of >0.15 and >1.0 mg/l have been correlated with
minimum and long-term protective immunity, respectively.
Analysis was made using the higher threshold.10 11
Pneumococcal capsular polysaccharide (PCP)-speciﬁc
IgG was measured using VaccZyme Anti-PCP Enzyme
Immunoassay kits (MK012, The Binding Site Ltd).
Microwells in the pneumococcal assay were supplied pre-
coated with 23 polysaccharide antigens, accounting for
80% of virulent serotypes (PCP antigens 1–5, 6B, 7F, 8,
9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20,
22F, 23F, 33F) and incorporated C-polysaccharide anti-
body absorption. Limits of quantiﬁcation for the assay
were 3.3–270.0 mg/dl. No level of protective immunity
has been established for a collective response to multiple
pneumococcal serotypes. A threshold value was there-
fore not used, but results were compared to published
age-based ranges using the same assay.12
Data management and statistical analysis
Where assay results were below the lower limit of quanti-
ﬁcation an arbitrary value of half the lower limit was
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assigned: anti-pertussis IgG 5 IU/ml,; anti-tetanus IgG
0.025 IU/ml; anti-Hib IgG 0.05 mg/dl; anti-PCP IgG
1.65 mg/dl.
Where assay results were above the upper limit of
quantiﬁcation samples were retested with serial dilutions
until a measurable value was obtained. This value was
then multiplied according to the dilution factor to
obtain the antibody level.
Statistical analyses were completed using IBM SPSS V.20
(SPSS Inc, Chicago, Illinois, USA) and GraphPad Prism
V.5.04 (GraphPad Software Inc, La Jolla, California, USA).
Two-sided p<0.05 was considered signiﬁcant. All compari-
sons were prespeciﬁed. The Mann-Whitney test was used
to compare geometric mean concentration (GMC) of spe-
ciﬁc IgG between groups, Spearman’s Rank Order was
used to assess correlations, Wilcoxon Signed-Rank test was
used to compare paired samples and proportions were
compared using Fisher’s exact test.
RESULTS
Study population
A total of 112 mother–infant pairs were enrolled in the
study. A further 275 women were invited to participate,
but declined. Reasons for non-participation were as
follows: not interested in participating in any research
(n=199); maternal blood sampling required (n=34);
infant blood sampling required (n=34) and involvement
in other research studies (n=7). There were 40 women
who were unable to provide informed consent and 58
women who fulﬁlled the stated exclusion criteria.
A blood sample was unobtainable for one mother and
three infants. The ﬁnal analysis was therefore based on
samples from 111 mothers and 109 infants (108
mother–infant pairs). Characteristics of the study cohort
are shown in table 1.
Maternal antibodies specific for pertussis, Hib, tetanus
and PCP
Figure 1 represents maternal speciﬁc antibodies titres.
The GMC of maternal speciﬁc antibody to pertussis was
19.19 IU/ml (95% CI 15.74 to 23.41 IU/ml); only 17%
(19/111) of women had a response regarded as protect-
ive. The GMC of speciﬁc IgG to Hib was 1.10 mg/l
(95% CI 0.83 to 1.45 mg/l); only 50% (56/111) of
women had levels of antibody likely to be associated
with long-term protection. High maternal levels of
anti-tetanus-speciﬁc antibody (GMC 0.38 IU/ml, 95% CI
0.29 to 0.49 IU/ml) were observed and the majority of
women had levels of antibody likely to be associated
with protection against tetanus (79%, 88/111). The
GMC of speciﬁc antibody to PCP (23 serotypes) among
mothers was 44.54 mg/l (95% CI 38.10 to 52.08 mg/l).
This is within the normal adult range.12 There was no
signiﬁcant difference in speciﬁc antibody titres between
HIV-infected and HIV uninfected women in this cohort
(ﬁgure 1) and inclusion of the data from HIV-infected
women in the overall analysis did not signiﬁcantly alter
the results (see online supplementary table S1).
Association between maternal-specific and infant-specific
antibody titres
There was a strong positive correlation between mater-
nal and infant speciﬁc antibody responses for pertussis
(rs=0.71, p<0.001), Hib (rs=0.80, p<0.001), tetanus
(rs=0.90, p<0.001) and pneumococcus (rs=0.85,
p<0.001).
Passively acquired infant specific antibodies to pertussis,
Hib, tetanus and PCP at birth
In line with the correlation between maternal and infant
antibody levels, newborn infants also had low levels of
speciﬁc antibodies to pertussis (GMC 28.40 IU/ml, 95%
CI 23.15 to 34.83 IU/ml) and Hib (GMC 0.65 mg/l,
95% CI 0.49 to 0.87; ﬁgure 2). Consequently, only 30%
(33/109) and 42% (46/109) of infants had protective
antibody levels to pertussis and Hib, respectively. Infant
GMC of speciﬁc antibody to tetanus was 0.41 IU/ml
(95% CI 0.29 to 0.57 IU/ml) and 82% (89/109) of
infants had protective levels of antibody. Infant GMC of
speciﬁc antibody to PCP was 42.85 mg/l (95% CI 36.63
Table 1 Subject characteristics
Subject characteristics n (%) n=112
Maternal age, median (IQR) 31.84 (27.22–35.66)
Maternal ethnicity
Asian or Asian British 8 (7%)
Black or Black British 34 (30%)
White British 20 (18%)
Other White background 26 (23%)
Mixed or other ethnic background 24 (22%)
Mother HIV-infected 12 (11%)
Gestation, median (IQR) in weeks 40 (39–41)
Female infant sex 55 (49%)
Infant delivered by caesarean section 44 (40%)
Birth weight, median (IQR) in kg 3.29 (2.99–3.60)
Exclusive breast-feeding at birth 70 (63%)
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Figure 1 Maternal specific antibody titres at time of delivery. HIV-uninfected women n=99. HIV-infected women n=12. Solid
horizontal line indicates geometric mean concentration. Dotted horizontal line indicates antibody level associated with protection
(where applicable). Groups compared using Mann-Whitney U test.
Figure 2 Infant specific antibody titres at birth. HIV-unexposed infants n=96. HIV-exposed, uninfected infants n=13. Solid
horizontal line indicates geometric mean concentration. Dotted horizontal line indicates antibody level associated with protection
(where applicable). Groups compared using Mann-Whitney U test. *p<0.05.
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to 50.13 mg/l), similar to the observed maternal GMC.
There was a signiﬁcant difference in speciﬁc antibody to
pneumococcus between HIV-exposed, uninfected
infants and HIV-unexposed infants, but no signiﬁcant
difference in any of the other speciﬁc antibodies tested
(ﬁgure 2, see online supplementary table S2).
Maternal HIV-infection and specific antibody responses
Within our study cohort, we identiﬁed a group of
women and infants who may be particularly vulnerable
to vaccine-preventable infections by nature of maternal
HIV-infection. We compared the placental transfer of anti-
body from HIV-infected women and their HIV-exposed,
uninfected infants with placental transfer of antibody from
HIV-uninfected women and their infants. All HIV-infected
women had received tailored prevention of mother to
child transmission (PMTCT) interventions as part of their
routine care and none of their infants were vertically
infected with HIV. The placental transfer of speciﬁc IgG to
pertussis, Hib, pneumococcus and tetanus was signiﬁcantly
reduced from HIV-infected mothers to their HIV-exposed,
uninfected infants (n=12 pairs) compared with
HIV-uninfected mothers and HIV-unexposed infants
(n=96 pairs) by 58% (p<0.001), 61% (p<0.001), 28%
(p=0.034) and 32% (p=0.035), respectively (table 2).
When the total placental transfer ratio (based on the ratio
of the total infant population GMC to the total maternal
population GMC was analysed, a similar reduction in pla-
cental transfer was observed in the context of maternal
HIV infection (see online supplementary table S3).
Uninfected infants born to HIV-infected mothers
(n=13) had signiﬁcantly lower levels of antibody to PCP
antigen compared with that of HIV-unexposed infants
(n=96) (24.2 mg/ml, 95% CI 17.1 to 34.3 mg/l, vs
46.3 mg/l, 95% CI 39.2 to 54.8 mg/ml, p=0.005), despite
similar levels of antibody between HIV-infected and unin-
fected mothers (ﬁgure 1). Antibody levels against Hib,
pertussis and tetanus were similar between HIV-exposed
and HIV-unexposed infants (ﬁgure 2, see online supple-
mentary table S2).
DISCUSSION
In this UK cohort only one in six women had a positive
antibody response to pertussis antigens that may be pro-
tective against disease. Placental transfer of pertussis IgG
was highly efﬁcient; however, in keeping with low maternal
antibody levels, less than one-third of newborn infants had
a potentially protective level of pertussis antibody. In the
context of the current pertussis epidemic, this suggests
that a signiﬁcant number of UK mothers and infants are at
risk. Maternal antibody levels against Hib were also low;
only 50% of mothers had antibody levels associated with
long-term protection. Since placental transfer of anti-Hib
IgG was less efﬁcient, the majority of infants (58%) had an
anti-Hib response below protective levels. By contrast, pla-
cental transfer of anti-tetanus IgG was highly efﬁcient, and
maternal antibody levels were high, consequently antibody
responses to tetanus in both mothers and infants in this
cohort are likely to be sufﬁcient to provide protection
against tetanus. The GMC of speciﬁc antibody to PCP (23
serotypes) among mothers was 44.54 mg/ml, which is
within the normal adult range.12 No speciﬁc level of
antibody to multiple pneumococcal serotypes has been
correlated with a protective response. Maternal speciﬁc
antibody levels were similar for pertussis, Hib, tetanus and
pneumococcus between HIV-infected and HIV-uninfected
women. However, the placental transfer of speciﬁc IgG to
pertussis, Hib, pneumococcus and tetanus was signiﬁcantly
reduced from HIV-infected mothers to their HIV-exposed,
uninfected infants compared with HIV-uninfected
mothers and HIV-unexposed infants. Despite this ﬁnding,
only responses to pneumococcus were signiﬁcantly lower
among uninfected infants born to HIV-infected mothers
compared with HIV-unexposed infants.
Despite renewed interest in the potential of maternal
immunisation to protect infants, data on baseline levels
of maternal speciﬁc antibody levels, and passively
acquired immunity in newborns, remain limited. Given
differences in natural exposure to disease, vaccination
strategies and genetic variation, baseline maternal and
infant antibody levels will vary between different popula-
tions. The major strength of our study lies in presenting
such data for a recent UK cohort.
Table 2 Influence of maternal HIV status on placental transfer of specific antibody
Median placental transfer (IQR)*
Per cent
reduction†
p
Value‡
HIV-infected mother: HIV-exposed,
uninfected infant pairs (n=12)
HIV-uninfected mother: HIV-
unexposed infant pairs (n=96)
Hib 0.29 (0.13–0.39) 0.74 (0.45–1.14) 61 0.0004
Pertussis 0.75 (0.66–0.95) 1.44 (1.04–1.87) 48 0.0002
Pneumococcus 0.73 (0.61–0.98) 1.02 (0.74–1.33) 28 0.0033
Tetanus 0.92 (0.51–1.46) 1.35 (1.00–1.75) 32 0.0036
*Placental transfer of mother to infant is expressed as ratio of infant-specific/maternal-specific IgG concentration at birth.
†Reduction in placental transfer between HIV-infected and HIV-uninfected women and their infants, calculated as (1—ratio of the placental
transfer from HIV-infected women/placental transfer from HIV-uninfected women)×100
‡Mann-Whitney U test.
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This data is in keeping with low levels of maternal
and infant pertussis and Hib antibody have also been
found in similar-sized cohort studies in the USA, the
Netherlands, Italy and South Africa.13–19
Our data also support recent studies which found that
placental transfer of IgG to protein antigens, such as
tetanus toxoid and pertussis toxin, shows active transport,
leading to infant antibody levels greater than maternal
levels.16 17 By contrast, placental transfer of IgG to polysac-
charide antigens, such as Hib and pneumococcal polysac-
charide antigens is much less efﬁcient, resulting in equal
or lower infant levels. This has been attributed to the
active transport of IgG1 subtype antibodies, predominantly
elicited by proteins, relative to the less-efﬁcient transport
of polysaccharide-elicited IgG2 antibodies.20 Conjugate
vaccines are now available to Hib and pneumococcus,
which could potentially elicit a greater IgG1 response.
Since these vaccines were only introduced in the UK in
1992 and 2006, respectively, we would expect very few of
the mothers in our cohort (median age 31.84) to have
received these vaccines. Therefore, any maternal antibody
response is likely to reﬂect natural exposure to polysac-
charide, resulting in a predominant IgG2 response and
consequently reduced placental transfer.
Our ﬁnding that maternal HIV-infection was associated
with reduced placental transfer is also consistent with
previous studies.20–24 Our data are of particular interest
since, in contrast to previous studies, all HIV-infected
women in this cohort were clinically stable and receiving
highly active retroviral therapy. One surprising ﬁnding in
our study is that, with the exception of lower antibody
levels against pneumococcus, reduced placental transfer
did not result in signiﬁcantly lower speciﬁc antibody levels
in HIV-exposed, uninfected infants compared with
HIV-unexposed infants. This is in contrast to our previous
work in South Africa.18 Although there were no signiﬁcant
differences in maternal antibody levels, a trend towards
higher antibody levels in the HIV-infected mothers for Hib,
pertussis and tetanus may have offset the effect of reduced
placental transfer. This may reﬂect population differences
between cohorts, different treatment regimes, or the limita-
tions of sample size in our UK HIV-infected subgroup.
It is of particular concern that maternal antibody
responses to pertussis antigens in this UK cohort were
very low, given the current pertussis epidemic. Pertussis
antibody levels decline within 2 years of both vaccination
and infection, however protective immunity may last
considerably longer.25 Waning vaccine-related immunity
is thought to explain a peak prevalence of pertussis
infection in adolescence.26 Since natural pertussis
immunity is thought to decline over 4–20 years postinfec-
tion, and almost half of all infants in the UK are born to
mothers aged over 30,27 28 it is not unexpected that
maternal pertussis immunity in the UK may be subopti-
mal. In addition, it has been established that passively
acquired immunity wanes rapidly in newborn infants,
with disappearance of maternal antipertussis IgG by
around 6 weeks of age.19 29 The new UK maternal
pertussis vaccination programme aims to increase mater-
nal and therefore infant antibody levels, extending the
period of passive immune protection.8 The low baseline
levels of immune response to pertussis shown in our UK
cohort suggest that this intervention has the potential to
be effective.
Natural immunity to Hib relies on recurrent subclin-
ical infection.30 The signiﬁcant reduction in Hib car-
riage rates in the community since the introduction of
effective immunisation in the UK in 1992 contributes to
a protective herd effect for neonates, and may also
explain the low level of maternal immunity in our
cohort. Numbers of cases of neonatal invasive infection
are currently too low to justify a programme of maternal
immunisation in the UK31; however, mortality for inva-
sive Hib disease remains high, and our data conﬁrm that
the majority of infants will not have protective levels of
immunity to Hib until primary vaccination is complete.
This supports the Health Protection Agency’s current
recommendations for prophylaxis of vulnerable house-
hold contacts of conﬁrmed invasive Hib infection.32
While tetanus is now rarely seen in the UK, it remains
a signiﬁcant cause of neonatal mortality worldwide. The
high antitetanus antibody levels observed in our cohort
may be due to the adolescent booster programme. High
maternal antibody levels coupled with efﬁcient placental
transfer of antibody ensures protective levels of antibody
in the majority of newborns. Universal maternal tetanus
immunisation in the UK is therefore unnecessary,
however worldwide remains an essential tool in the elim-
ination of neonatal and maternal tetanus and an excel-
lent example of the potential utility of maternal
immunisation to reduce infant mortality.3 33
Like Hib, invasive pneumococcal disease has become
less common in the UK since the addition of pneumococ-
cal conjugate vaccines to the infant immunisation sched-
ule.34 Carriage rates of serotypes included in these
vaccines have also reduced, providing some protection
through herd immunity for neonates.35 However concerns
remain regarding a rise in carriage and invasive disease
due to non-vaccine serotypes, with over 100 cases of non-
vaccine serotype invasive pneumococcal disease in infants
less than 2 years in the UK in 2011–2012.36 While there
is no validated correlate of protection for collective
response to multiple pneumococcal serotypes, our ﬁnding
of lower pneumococcal antibody levels in HIV-exposed
infants is of some concern. In developing world settings,
HIV-exposure, even without HIV-infection, is associated
with an increased risk of severe pneumonia.37 While the
mortality risk for HIV-exposed, uninfected, infants in a UK
setting is likely to be lower, our data suggest that this popu-
lation remains vulnerable to invasive pneumoccocal
disease. Previous studies of maternal immunisation to
prevent pneumococcal disease in infants have demon-
strated an increased immune response in mothers and
infants lasting several months38–42; however, a recent sys-
tematic review concluded there was insufﬁcient evidence
that maternal pneumococcal immunisation reduced
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neonatal infection.43 Included trials were limited by small
sample size, and all used the (unconjugated) pneumococ-
cal polysaccharide vaccine. While this vaccine offers cover-
age for a larger number of serotypes, pneumococcal
conjugate vaccines could theoretically offer the advantage
of producing IgG1 antibodies with more efﬁcient placen-
tal transfer. Larger clinical trials are required to assess the
potential impact of maternal pneumococcal immunisation
in infants, particularly infants exposed to HIV.
Our study has a number of limitations, one of which is
enrolment of a modest number of mother–infant pairs at
a single centre. Consecutive sampling ensured that our
cohort accurately reﬂected families accessing care in this
central London hospital; however this ethnically diverse
population, with a high proportion of HIV-infected
mothers, may not be representative of all areas in the UK.
Another potential limitation of this study is the use of a
mixed pertussis antigen (PT/FHA) ELISA to assess anti-
body response. This assay was chosen to allow comparison
to previously published work18 and because both PT and
FHA are vaccine antigens present in all licensed vaccines in
Europe. The use of ELISAs that measure these antibodies
separately may however have allowed easier comparison to
other studies. Another concern is that mixed antigen assays
have been found to be less speciﬁc in the diagnosis of per-
tussis.44 Published recommendations for the diagnosis of
pertussis infection state that PT-speciﬁc antibodies alone
should be measured; however, these recommendations
acknowledged that measurement of antibodies to other
pertussis antigens may be appropriate in immunogenicity
studies.45 Although both sensitivity and speciﬁcity of the
assay used in this study have previously been reported to be
95%,46 a more recent study-reported speciﬁcity to be only
56%.44 If the speciﬁcity of our pertussis assay is low we may
have overestimated maternal-speciﬁc pertussis antibody
levels, and therefore may have underestimated the propor-
tion of mothers and infants susceptible to pertussis. Our
main conclusion, that pertussis antibody levels in this
cohort are worryingly low, remains unchanged.
Maternal immunisation has a sound theoretical basis
and has been proven to increase levels of maternal and
infant antibody for a number of infectious diseases, but
with the exception of tetanus the efﬁcacy of this strategy
in reducing infant mortality needs further study.47 48
The introduction of maternal pertussis immunisation in
the UK offers an excellent opportunity for a large
population-based study to assess impact of this pro-
gramme on maternal seroprevalence and national rates
of infant pertussis infection. In addition, more data is
needed to resolve concerns that high levels of maternal
antibody diminish infant active immune response to vac-
cination. While recent studies suggest this does not
affect efﬁcacy of the acellular pertussis vaccine,48 49 it
would be prudent to assess this further by comparing
infant immune responses postvaccination in infants of
mothers who received the pertussis vaccination to a
control group of those who did not.
Finally, a challenge to the introduction of the maternal
pertussis vaccination campaign will be achieving acceptabil-
ity and therefore uptake among pregnant women. Reports
suggest initial uptake of the maternal pertussis vaccine in
the UK is relatively high at 50%.50 However, such promising
early results would only be maintained and improved if
pregnant women, and their healthcare providers, were con-
vinced that the beneﬁts are very clear and there were no
safety concerns. As has been observed with the inﬂuenza
vaccination, where uptake among pregnant women in
England was only 27.4% in 2011/2012,51 important barriers
to implementation of these potentially life-saving interven-
tions exist. Evidence-based strategies to increase public and
practitioner acceptability of maternal immunisation are
required.47
Infant immunisation remains one of the most success-
ful tools in reducing child morbidity and mortality
worldwide. Maternal immunisation offers the potential
to extend this success story to protect our youngest and
most vulnerable children.
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